PMID- 35718789
OWN - NLM
STAT- MEDLINE
DCOM- 20220621
LR  - 20220716
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 17
IP  - 1
DP  - 2022 Jun 20
TI  - Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan 
      Union Hospital Cancer Center.
PG  - 109
LID - 10.1186/s13014-022-02081-8 [doi]
LID - 109
AB  - BACKGROUND: To analyze and explore the evolution and short-term efficacy of 
      neoadjuvant therapy for patients with mid and low LARC in Wuhan Union Hospital 
      Cancer Center. METHODS: Patients diagnosed with rectal cancer from January 2015 
      to December 2021 were collected. The treatment patterns, short-term efficacy and 
      treatment-related adverse events (AEs) of mid and low LARC patients who received 
      neoadjuvant therapy were analyzed. The Chi-square test was used to compare the 
      differences between groups. RESULTS: A total of 980 patients with mid and low 
      LARC were enrolled, over time, the proportion of patients receiving neoadjuvant 
      therapy gradually increased, and the treatment mode of direct surgery after 
      diagnosis was gradually watered down. More than 80% of the patients implemented 
      radiotherapy-based neoadjuvant therapy, and the proportion of patients receiving 
      SCRT sequential systemic therapy gradually exceeded that of LCRT combined 
      chemotherapy after 2020. Of all patients who completed radiotherapy and underwent 
      surgery, 170 patients received long-course chemoradiotherapy (LCRT) combined with 
      chemotherapy (Group C) and 98 patients received short-course radiotherapy (SCRT) 
      combined with systemic therapy (chemotherapy with or without immunotherapy) 
      (Group D). The pathological complete response (pCR) rate in Group D was 
      significantly higher than that in Group C (38.8% vs. 19.4%, P = 0.001). The pCR 
      rate in the SCRT plus immunotherapy group was better than that in the group 
      without immunotherapy (49.2% vs. 21.6%, P = 0.007). 82.3% of the patients 
      receiving immunotherapy were treated with SCRT sequential 2-cycle CapOX plus 
      Camrelizumab treatment, and the pCR was as high as 52.9%. Immunotherapy did not 
      increase the incidence of Grade 3-4 AEs. CONCLUSIONS: Neoadjuvant therapy based 
      on radiotherapy is becoming used in patients with mid and low LARC. SCRT 
      sequential systemic therapy is increasingly widely used in LARC patients in our 
      center. Compared with the traditional LCRT or SCRT sequential chemotherapy, SCRT 
      sequential chemotherapy plus immunotherapy has a remarkable pCR rate and 
      manageable toxicity. Looking forward this new treatment mode will bring lasting 
      survival benefits to patients.
CI  - (c) 2022. The Author(s).
FAU - Zhai, Meng-Lan
AU  - Zhai ML
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Zhang, Fang-Yuan
AU  - Zhang FY
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Yang, Jin-Ru
AU  - Yang JR
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Zhang, Sheng
AU  - Zhang S
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Zhao, Lei
AU  - Zhao L
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Lin, Zhen-Yu
AU  - Lin ZY
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Yu, Dan-Dan
AU  - Yu DD
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China. yudandan@hust.edu.cn.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of 
      Science and Technology, Wuhan, 430022, China. taozhangxh@hust.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220620
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Chemoradiotherapy
MH  - Hospitals
MH  - Humans
MH  - Neoadjuvant Therapy/adverse effects
MH  - *Neoplasms, Second Primary/etiology
MH  - *Rectal Neoplasms/pathology
MH  - Rectum/pathology
PMC - PMC9208162
OTO - NOTNLM
OT  - Long course chemoradiotherapy
OT  - Neoadjuvant therapy
OT  - Pathological complete response
OT  - Rectal cancer
OT  - Short-course radiotherapy
COIS- The authors declare that they have no competing interests.
EDAT- 2022/06/20 06:00
MHDA- 2022/06/22 06:00
PMCR- 2022/06/20
CRDT- 2022/06/19 23:14
PHST- 2022/04/08 00:00 [received]
PHST- 2022/06/10 00:00 [accepted]
PHST- 2022/06/19 23:14 [entrez]
PHST- 2022/06/20 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/06/20 00:00 [pmc-release]
AID - 10.1186/s13014-022-02081-8 [pii]
AID - 2081 [pii]
AID - 10.1186/s13014-022-02081-8 [doi]
PST - epublish
SO  - Radiat Oncol. 2022 Jun 20;17(1):109. doi: 10.1186/s13014-022-02081-8.